```
=> d his

     (FILE 'HOME' ENTERED AT 14:49:04 ON 12 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 14:50:34 ON 12 MAR 2005
L1               STRUCTURE UPLOADED
L2             0 S L1
L3            82 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:51:09 ON 12 MAR 2005
L4            23 S L3

=> d que l4 stat
L1               STR
```





G1 O,S

G2 [@1],[@2],[@3]

G3 H,Ak

Structure attributes must be viewed using STN Express query preparation.

```
L3            82 SEA FILE=REGISTRY SSS FUL L1
L4            23 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3

=> d 1-23 bib abs hitstr
```

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:698112 CAPLUS
DN 141:200194
TI New combinations and new use of selected pharmaceutically active tricyclic
imidazo[1,2-a]pyridine compounds for preventing or treating medicament-caused gastrointestinal diseases
IN Zimmermann, Peter Jan; Palmer, Andreas; Brehm, Christof; Klein, Thomas; Senn-Bilfinger, Joerg; Simon, Wolfgang-Alexander; Postius, Stefan; Chiesa,
M. Vittoria; Buhr, Wilm; Kromer, Wolfgang
PA Altana Pharma Ag, Germany
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004071391	A2	20040826	WO 2004-EP50138	20040216
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI EP 2003-3530	A	20030217		

AB The present invention relates to new combinations and new use of certain selected tricyclic imidazo[1,2-a]pyridine compds. in the prevention or treatment of medicament-caused gastrointestinal diseases. At 3.0 μmol/kg, (7R,8R,9R)-8-hydroxy-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine reduced gastric lesions induced by 100 mg/kg acetylsalicylic acid in rats.
IT **109543-76-2**, ROMazaRIT
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as second active agent; new combinations and new use of selected pharmaceutically active tricyclic imidazo[1,2-a]pyridine compds. for preventing or treating medicament-caused gastrointestinal diseases)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:855743 CAPLUS
DN 139:335104
TI Gelsolin as a prognostic marker of atherosclerotic diseases
IN Stossel, Thomas P.
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003088811	A2	20031030	WO 2003-US11722	20030416
WO 2003088811	A3	20040226		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI US 2002-373043P	P	20020416		

AB This invention involves the using blood gelsolin levels as a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction, stroke, and peripheral ischemic cardiovascular disease, particularly among subjects with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which subjects at risk will
preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders.
IT **109543-76-2**, Romazarit
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelsolin as prognostic marker of atherosclerotic diseases)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:377132 CAPLUS
DN 138:367144
TI Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
IN Schoenbeck, Uwe; Ridker, Paul M.; Libby, Peter
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040691	A2	20030515	WO 2002-US35505	20021105
WO 2003040691	A3	20031113		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003152566	A1	20030814	US 2002-288253	20021105
EP 1451577	A2	20040901	EP 2002-780578	20021105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
PRAI US 2001-338841P	P	20011105		
WO 2002-US35505	W	20021105		

AB The invention involves the new use of a diagnostic test to determine the risk
of atherosclerotic diseases, e.g. myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, the invention involves the new use
of a diagnostic test to assist physicians in determining which individuals at
risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.
IT **109543-76-2**, Romazarit
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble CD40L as prognostic marker of atherosclerotic diseases, and use
in therapeutic agent assessment)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:242192 CAPLUS

DN 138:248511

TI Combination of phosphodiesterase 4 inhibitor and nonsteroidal antiinflammatory drug in treatment of inflammation

IN Hatzelmann, Armin; Eltze, Manfrid; Klein, Thomas; Kley, Hans-Peter

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024489	A2	20030327	WO 2002-EP10424	20020917
	WO 2003024489	A3	20030918		
	W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, SI, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	EP 1429807	A2	20040623	EP 2002-772313	20020917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012606	A	20040817	BR 2002-12606	20020917
	JP 2005504077	T2	20050210	JP 2003-528583	20020917
	US 2004242597	A1	20041202	US 2004-489920	20040318
PRAI	EP 2001-473	A	20010919		
	WO 2002-EP10424	W	20020917		

AB The invention relates to the combined administration of PDE4-inhibitors and NSAIDs for the treatment of an inflammatory disease and/or an inflammation associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of NSAIDs. PDE4 inhibitors Rolipram, Roflumilast, and RP73401 inhibited or prevented diclofenac induced gastrointestinal bleeding in mice.

IT 109543-76-2, ROMAZARIT
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NSAID; combination of phosphodiesterase 4 inhibitor and nonsteroidal antiinflammatory drug in treatment of inflammation)

RN 109543-76-2 CAPLUS

CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:868433 CAPLUS

DN 136:20062

TI Preparation of heterocyclic compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.

IN Kuwabara, Kenji; Aoki, Tomiyoshi

PA Nippon Shinyaku Co., Ltd., Japan

SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062

AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic heterocyclic group; Het is a divalent aromatic heterocyclic group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.

IT 377731-41-4P 377731-71-0P 377731-72-1P
377731-73-2P 377731-74-3P 377731-75-4P
377731-76-5P 377731-77-6P 377731-78-7P
377731-79-8P 377731-80-1P 377731-81-2P
377731-82-3P 377731-87-8P 377731-88-9P

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
377731-69-0P 377732-26-8P 377732-33-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)
RN 377731-41-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[[6-(2-phenyl-4-oxazolyl)hexyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 377731-71-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[6-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]hexyl]oxy]- (9CI) (CA INDEX NAME)



RN 377731-72-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[[6-(5-methyl-2-phenyl-4-oxazolyl)-4-hexynyl]oxy]- (9CI) (CA INDEX NAME)



RN 377731-73-2 CAPLUS
CN Propanoic acid, 2-[[6-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]hexyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 377731-78-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[[7-(2-phenyl-4-oxazolyl)heptyl]oxy]- (9CI) (CA INDEX NAME)



RN 377731-79-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[8-(2-phenyl-4-oxazolyl)octyl]oxy]- (9CI) (CA INDEX NAME)



RN 377731-80-1 CAPLUS
CN Propanoic acid, 2-[[7-[2-(4-chlorophenyl)-4-oxazolyl]heptyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 377731-81-2 CAPLUS
CN Propanoic acid, 2-[[7-[2-(4-fluorophenyl)-4-oxazolyl]heptyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 377731-74-3 CAPLUS
CN Propanoic acid, 2-[[6-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]hexyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 377731-75-4 CAPLUS
CN Propanoic acid, 2-[[6-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]hexyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 377731-76-5 CAPLUS
CN Propanoic acid, 2-[[6-(5-ethyl-2-phenyl-4-oxazolyl)hexyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 377731-77-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[6-(2-phenyl-4-oxazolyl)hexyl]oxy]- (9CI) (CA

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 377731-82-3 CAPLUS
CN Propanoic acid, 2-[[6-[2-(4-fluorophenyl)-4-oxazolyl]hexyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 377731-87-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[(4E)-6-(5-methyl-2-phenyl-4-oxazolyl)-4-hexenyl]oxy]-, potassium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● K

RN 377731-88-9 CAPLUS
CN 1-Propanol, 2-methyl-2-[[6-(5-methyl-2-phenyl-4-oxazolyl)hexyl]oxy]- (9CI)
(CA INDEX NAME)



RN 377731-89-0 CAPLUS
CN 1-Propanol, 2-[[6-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]hexyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 377732-26-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[6-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]hexyl]thio]- (9CI) (CA INDEX NAME)



RN 377732-33-7 CAPLUS
CN Propanamide, N-hydroxy-2-methyl-2-[[6-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]hexyl]oxy]- (9CI) (CA INDEX NAME)



IT 377733-08-9 377733-09-0 377733-13-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as remedies for hyperlipidemia, and
arteriosclerosis, and diabetes and obesity)
RN 377733-08-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[(4E)-6-(5-methyl-2-phenyl-4-oxazolyl)-4-hexenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 377733-09-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[6-(5-methyl-2-phenyl-4-oxazolyl)hexyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 377733-13-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[(4E)-6-(5-methyl-2-phenyl-4-oxazolyl)-4-hexenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:851134 CAPLUS
DN 135:371737
TI Preparation of phenyloxazole compounds as fungicides for agricultural and horticultural use
IN Ueda, Akiyoshi; Kubota, Yasushi; Suga, Shigemi; Sano, Hiroshi; Hamamura, Hiroshi
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001087857	A1	20011122	WO 2001-JP4075	20010516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI JP 2000-143924	A	20000516		

OS MARPAT 135:371737
GI



I

AB Title compds. [I; X = CY, N; X1 = CY2, N; Y = H, CH3, NO2, CH(OH)CH3, CH(OCOCH3)CH3, ; Y1 = H, CH3, Br, CF3, Cl, CN, CHO, CH2C6H5, CH2Cl, CH:NC6H5, CH2CCH, CH(CH3)2, CH:NOCH2CH2Cl, CH2OCH2CH2OCH3, CH2SCH3, NO2, OCH3, OCH3, SCH3, CH2CN; Z = O, S, SO, SO2, NH, N(CH2)5CH3, NCH2CH3, NCH3, N(CH2)3CH3; R = H, CH3, CH2CH2OH, COOCH2CH3, COCH3, COCH2Cl, CH2CCH, CH2CCl, COC(CH3)3, CONHC6H5, COCH2OCH3, COCH2OCH2CCH, CH2CH3, CH2CH2CH3, (CH2)3CH3; R1 = H, 5-OCH3, 5-Br, 5-CH3, 5-Cl, 5-F, 5-OH, 5-NO2; ZR = N((CH2)2)2CH2, N((CH2)2)2O, N((CH2)2),etc.] and salts thereof, are prepared with industrial advantage and are useful as fungicides for agricultural and horticultural use exhibiting excellent fungicidal effects not only on pathogenic fungi sensitive to fungicides but also on those resistant fungi. Thus, the title compound I (X = CH; X1 = N; Y1 = H; R1 = H; Z = O; R = COCH3) was prepared and biol. tested.
IT 374638-88-7P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenyloxazole compds. as fungicides for agricultural and

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
horticultural use)
RN 374638-88-7 CAPLUS
CN Propanoic acid, 2-[[5-(4-hydroxy-3-nitrophenyl)-2-oxazolyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:630558 CAPLUS
DN 136:303400
TI Strategy in metabolite isolation and identification
AU Wiltshire, Hugh
CS Roche Discovery Welwyn, Welwyn Garden City, AL7 3AY, UK
SO Principles and Practice of Bioanalysis (2000), 302-341. Editor(s): Venn, Richard P. Publisher: Taylor & Francis Ltd., London, UK.
CODEN: 69BSM6
DT Conference; General Review
LA English
AB A review with refs. discusses the techniques applied for the isolation of metabolite from biol. material. Only by using a combination of extraction and chromatog. techniques will it be possible to design an efficient procedure for the isolation and identification of the metabolites produced by a complex catabolic process. The five stages for the technique, such as radiochem. synthesis, animal expts., metabolite isolation and characterization, identification of metabolites, and quant. aspects of metabolism, are described. The in vivo studies, identification of plasma metabolites, and good laboratory practice are also discussed.
IT **109543-76-2**, Romazarit
RL: ANT (Analyte); PKT (Pharmacokinetics); ANST (Analytical study); BIOL (Biological study)
(strategy in metabolite isolation and identification)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:630544 CAPLUS
DN 136:303399
TI Physico-chemical properties of drugs and metabolites and their extraction from biological material
AU Wiltshire, Hugh
CS Roche Discovery Welwyn, Welwyn Garden City, AL7 3AY, UK
SO Principles and Practice of Bioanalysis (2000), 1-27. Editor(s): Venn, Richard P. Publisher: Taylor & Francis Ltd., London, UK.
CODEN: 69BSM6
DT Conference; General Review
LA English
AB A review with refs. discusses the physico-chemical properties of drugs and solvents. Topics discussed also include the partition coefficient for a compound undergoing an aqueous/organic separation; ionization and its effect on the extraction of drugs; solvent extraction; and the 'first law of drug metabolism'.
IT **109543-76-2**, Romazarit
RL: PRP (Properties)
(physico-chemical properties of drugs and metabolites and extraction from biol. material)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:167849 CAPLUS
DN 134:217194
TI Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
IN Ridker, Paul; Hennekens, Charles H.
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015744	A1	20010308	WO 2000-US24251	20000831
	WO 2001015744	C2	20020926		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2381926	AA	20010308	CA 2000-2381926	20000831
	EP 1212101	A1	20020612	EP 2000-959851	20000831
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	JP 2003508453	T2	20030304	JP 2001-520155	20000831
PRAI	US 1999-387028	A	19990831		
	WO 2000-US24251	W	20000831		

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder such as atherosclerosis, stroke, and myocardial infarction by assessing the level of systemic inflammation marker (such as sICAM or C-reactive protein) in an individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorders; and of drug combinations (anti-inflammatory agents, lipid-reducing agents, angiotensisin system inhibitors, calcium channel blockers, β-adrenergic receptor blockers) suitable for prevention future cardiovascular disease.
IT **109543-76-2**, Romazarit
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of agents and systemic inflammatory markers to predict and inhibit cardiovascular diorders in humans)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:682113 CAPLUS
DN 129:299893
TI Means of ascertaining an individual's risk profile for atherosclerotic disease based on systemic inflammation marker levels
IN Ridker, Paul; Hennekens, Charles H.
PA Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843630	A1	19981008	WO 1998-US6613	19980402
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2285091	AA	19981008	CA 1998-2285091	19980402
	AU 9871008	A1	19981022	AU 1998-71008	19980402
	US 6040147	A	20000321	US 1998-54212	19980402
	EP 1003501	A1	20000531	EP 1998-917992	19980402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001525058	T2	20011204	JP 1998-542023	19980402
	JP 2003128582	A2	20030508	JP 2002-220353	19980402
	EP 1493439	A1	20050105	EP 2004-10424	19980402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI	US 1997-41950P	P	19970402		
	US 1997-43039P	P	19970402		
	US 1998-70894P	P	19980109		
	EP 1998-917992	A3	19980402		
	JP 1998-542023	A3	19980402		
	WO 1998-US6613	W	19980402		

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder. The primary basis for this invention is evidence from the Physicians' Health Study, a large scale, randomized, double-blind, placebo-controlled trial of aspirin and β-carotene in the primary prevention of cardiovascular disease conducted among 22,000 apparently healthy men. In that trial, baseline level of C-reactive protein, a marker for underlying systemic inflammation, was found to determine the future risk of myocardial infarction and stroke, independent of a large series of lipid and non-lipid risk factors. Baseline C-reactive protein level was not associated with venous thrombosis, a vascular event generally not associated with atherosclerosis. Further, the data indicate that the magnitude of benefit that apparently healthy individuals can expect from prophylactic aspirin is dependent in large part upon baseline level of C-reactive protein.
IT **109543-76-2**, Romazarit

L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(systemic inflammation marker level in evaluation of cardiovascular disorder risk redn. by)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:374878 CAPLUS
DN 126:338852
TI A pharmaceutical composition using a cytokine-suppressing anti-inflammatory agent and an immunosuppressant for the treatment of autoimmune diseases
IN Guglielmotti, Angelo; Dionisio, Paolo
PA Angelini Ricerche S.P.A. Societa' Consortile, Italy; Guglielmotti, Angelo; Dionisio, Paolo
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9716185	A2	19970509	WO 1996-EP4672	19961026
	WO 9716185	A3	19970703		
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2236256	AA	19970509	CA 1996-2236256	19961026
	AU 9674938	A1	19970522	AU 1996-74938	19961026
	AU 721841	B2	20000713		
	EP 858337	A2	19980819	EP 1996-937258	19961026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1207042	A	19990203	CN 1996-199472	19961026
	BR 9611320	A	19990302	BR 1996-11320	19961026
	JP 11515020	T2	19991221	JP 1996-517053	19961026
	NZ 321580	A	20000228	NZ 1996-321580	19961026
	IL 124291	A1	20010614	IL 1996-124291	19961026
	CZ 292258	B6	20030813	CZ 1998-1326	19961026
	PL 186377	B1	20031231	PL 1996-326371	19961026
	SK 284069	B6	20040908	SK 1998-579	19961026
	ZA 9609060	A	19970529	ZA 1996-9060	19961028
	NO 9801951	A	19980629	NO 1998-1951	19980429
	US 6020356	A	20000201	US 1998-68011	19980903
PRAI	IT 1995-MI2242	A	19951031		
	WO 1996-EP4672	W	19961026		

AB A pharmaceutical composition is disclosed which comprises an anti-inflammatory drug capable of suppressing the production of cytokines (CSAID), an immunosuppressant, and a pharmaceutically acceptable excipient. Use of CSAIDS allow reduction of the immunosuppressant dose in the prolonged treatment of autoimmune disease without reducing therapeutic efficacy, thus improving tolerability. Results of a clin. study shows that bindarit significantly reduced the the severity of nephritis complications in patients suffering from systemic lupus erythematosus treated with corticosteroids.
IT **109543-76-2**, Romazarit
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Uses)
(cytokine-suppressing anti-inflammatory agent and immunosuppressant for autoimmune disease treatment)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:53966 CAPLUS
DN 126:74828
TI Preparation of substituted oxazoles as antiinflammatories.
IN Talley, John J.; Bertenshaw, Stephen; Rogier, Donald J., Jr.; Graneto, Matthew; Brown, David L.; Devadas, Balekudru; Lu, Hwang-Pun; Sikorski, James A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9636617	A1	19961121	WO 1996-US6992	19960516
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2221692	AA	19961121	CA 1996-2221692	19960516
AU 9658603	A1	19961129	AU 1996-58603	19960516
EP 825989	A1	19980304	EP 1996-920231	19960516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11509835	T2	19990831	JP 1996-535029	19960516
PRAI US 1995-445312	A	19950519		
WO 1996-US6992	W	19960516		

OS MARPAT 126:74828
GI



I

AB Title compds. (I; R2 = alkyl, amino; R4 = H, alkyl, alkylamino, alkoxy, halo; R5 = halo, SH, carboxyalkylthio, aminocarbonyl, amino acid residue, haloalkoxy, aryloxy, phosphonylalkyl, cyanoalkyl, heterocyclylalkyl, etc.), were prepared Thus, 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-methylsulfonyphenyl)oxazole, prepared from 1-(4-fluorophenyl)-2-(4-methylthiophenyl)ethanone, at 10 mg/kg gave 41% inhibition of edema in the carrageenan foot pad edema test.

L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 185343-76-4 CAPLUS
CN Acetic acid, [[2-[5-[4-(aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]ethyl]thio]- (9CI) (CA INDEX NAME)



RN 185343-77-5 CAPLUS
CN Acetic acid, [[[5-[4-(aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 185343-78-6 CAPLUS
CN Acetic acid, [[[5-[4-(aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]methyl]thio]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 185343-25-3P 185343-66-2P 185343-75-3P
185343-76-4P 185343-77-5P 185343-78-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxazoles as antiinflammatories)
RN 185343-25-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-4-phenyl-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185343-66-2 CAPLUS
CN Acetic acid, [[5-[4-(aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 185343-75-3 CAPLUS
CN Acetic acid, [[2-[5-[4-(aminosulfonyl)phenyl]-4-phenyl-2-oxazolyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:950578 CAPLUS
DN 124:117155
TI Reaction of N-benzoyl amino acids with oxalyl chloride: a facile route to 4-substituted 2-phenyloxazole-5-carboxylates
AU Cynkowski, Tadeusz; Cynkowska, Grazyna; Ashton, Paul; Crooks, Peter A.
CS College Pharmacy, Univ. Kentucky, Lexington, KY, 40536-0082, USA
SO Journal of the Chemical Society, Chemical Communications (1995), (22), 2335-6
CODEN: JCCCAT; ISSN: 0022-4936
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 124:117155
GI



I

AB N-Benzoyl amino acids PhCONHCHR1CO2H (R1 = H, Me, PhCH2, Me2CH, MeSCH2CH2, etc.) react with excess ClCOCOCl at room temperature followed by addition of alcs. to afford 4-substituted 2-phenyloxazole-5-carboxylates I (R2 = Me, Et).
IT 173037-43-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phenyloxazolecarboxylates by cyclization of benzoyl amino acids with oxalyl chloride)
RN 173037-43-9 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-21-[[[4-(3-methoxy-3-oxopropyl)-2-phenyl-5-oxazolyl]carbonyl]oxy]-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:630762 CAPLUS
DN 121:230762
TI 4-Methyl-1,3-oxazole derivatives, process for their preparation, and antiinflammatory pharmaceutical compositions containing them
IN de Nanteuil, Guillaume; Vincent, Michel; Lila, Christine; Bonnet, Jacqueline; Fradin, Armel
PA Adir et Cie., Fr.
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 601930	A1	19940615	EP 1993-402967	19931209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2699172	A1	19940617	FR 1992-14912	19921211
FR 2699172	B1	19950120		
AU 9352300	A1	19940623	AU 1993-52300	19931209
AU 665285	B2	19951221		
US 5468761	A	19951121	US 1993-164464	19931209
CA 2111152	AA	19940612	CA 1993-2111152	19931210
ZA 9309283	A	19940818	ZA 1993-9283	19931210
JP 06239842	A2	19940830	JP 1993-310639	19931210
JP 2579116	B2	19970205		
PRAI FR 1992-14912	A	19921211		

OS MARPAT 121:230762
GI



I II

AB Title compds. I [R1 = 1-adamantyl, dicyclopropylmethyl, (halo)cycloalkyl, OH, alkoxy, (4-substituted) bicyclo[2.2.2]oct-1-yl; R2 = CH2OCOCMe2OH, (CH2)mX(CH2)nCR3R4COR5; m = 1-3; X = O, S, NR; R = H, alkyl; R3, R4 = H, alkyl, CF3; or CR3R4 = cycloalkylidene; n = 0-2; R5 = OH, alkoxy, (di)(alkyl)amino, OCH2CONR'R''; R', R'' = alkyl; or NR'R'' = 5- or 6-membered heterocyclyl] and their enantiomers, diastereomers, epimers, and salts, are prepared as antiinflammatories and antiarthritics. For example, 1-adamantanecarboxylic acid reacted with Na2CO3 and MeCOCHClCO2Et in DMF to give Et 2-(1-adamantyl)carbonyloxyacetoacetate, which was cyclized with formamide in the presence of H2SO4 to give oxazole derivative II. This underwent reduction of the the ethoxycarbonyl group to hydroxymethyl using LiAlH4, and the hydroxymethyl compound was condensed with Me2CO and CHCl3 in the presence of NaOH to give I [R1 = 1-adamantyl; R2 = CH2OCMe2CO2Et], isolated as its Na salt. In the Freund's adjuvant arthritis model in rats, 3 compds. I gave 27-47% correction of hypoalbuminemia, vs. only 1% for the structurally similar drug romazarit.
IT 158196-70-4P 158196-71-5P 158196-75-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory and antiarthritic)

L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 158196-70-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[(4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-5-oxazolyl)methoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 158196-71-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[(4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-5-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 158196-75-9 CAPLUS
CN Propanoic acid, 2-[[2-(4-methoxycyclohexyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:620722 CAPLUS
DN 121:220722
TI Romazarit
AU Bradshaw, David; Williams, Peter E. O.
CS Roche Prod. Ltd., Welwyn Garden City/Hertsfordshire, UK
SO Nonsteroidal Anti-Inflammatory Drugs (2nd Ed.) (1994), 317-32. Editor(s):
Lewis, Alan J.; Furst, Daniel E. Publisher: Dekker, New York, N.Y.
CODEN: 59YXAB
DT Conference; General Review
LA English
AB A review with 11 refs.on the pharmacol. protperties of antirheumatic romazarit.
IT **109543-76-2**, Romazarit
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(antirheumatic pharmacol.)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:239875 CAPLUS
DN 114:239875
TI Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers
AU Williams, P. E. O.; Muirhead, G. J.; Worth, E.; Zimmer, R.; Luecker, P.
CS Pharmacokinet. Metab. Dep., Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SO European Journal of Drug Metabolism and Pharmacokinetics (1990), 15(4), 317-22
CODEN: EJDPD2; ISSN: 0398-7639
DT Journal
LA English
AB The pharmacokinetics and tolerability of romazarit, a potential antirheumatic drug, were studied in healthy men given single oral doses of 40 to 1500 mg. Plasma and urinary concns. of romazarit were measured by HPLC with UV detection. Model-independent pharmacokinetic analyses showed that romazarit was rapidly and extensively absorbed in a dose-proportional manner. Urinary recovery of drug-related material was .apprx.70% of the dose and almost all in the form of labile metabolites (probably acyl glucuronides). Clearance was faster (>3 L/h) at doses below <700 mg, than in the range of 700-1500 mg (1.7 L/h). Two or more clearance mechanisms may be present. One of these mechanisms is saturable and may involve a reversible ester glucuronide formation coupled with saturable tubular secretion of glucuronides. Romazarit was well tolerated. There were two reports of stomach pain, one associated with vomiting. Changes in laboratory test results and in measurements of vital signs were similar in frequency and magnitude after romazarit and placebo administration.
IT **109543-76-2**, Romazarit
RL: BIOL (Biological study)
(pharmacokinetics and tolerability of, in humans)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:81671 CAPLUS
DN 114:81671
TI Romazarit. A potential disease-modifying antirheumatic drug
AU Self, Christopher R.; Barber, William E.; Machin, Peter J.; Osbond, John M.; Smithen, Carey E.; Tong, Brian P.; Wickens, James C.; Bloxham, David P.; Bradshaw, David; et al.
CS Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SO Journal of Medicinal Chemistry (1991), 34(2), 772-7
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 114:81671
GI



I

AB A series of 4-chlorophenylazolylmethoxyisobutyric acids were prepared They were evaluated for antiinflammatory effects in adjuvant arthritis and type II collagen arthritis in the rat. The desired profile of biol. activity was characterized by the reduction of inflammation into the coincident restoration towards normal levels of the biochem. markers (acute phase proteins) associated with the inflammatory response, an effect that was not shared by classical nonsteroidal antiinflammatory agents. Romazarit (I) was selected for further evaluation. I was inactive in animal models of acute inflammation, and furthermore it did not inhibit cyclooxygenase in vitro or in vivo. Inhibition of interleukin-1-mediated events in vitro has been observed
IT **109543-76-2P 109543-97-7P 109543-98-8P 109543-99-9P 109544-01-6P 109544-03-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antirheumatic activity of)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-97-7 CAPLUS

L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-5-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



RN 109543-98-8 CAPLUS
CN Propanoic acid, 2-[[5-(4-chlorophenyl)-2-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



RN 109543-99-9 CAPLUS
CN Propanoic acid, 2-[[4-(4-chlorophenyl)-2-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



RN 109544-01-6 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 109544-03-8 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:229444 CAPLUS
DN 112:229444
TI Biologic properties of romazarit (Ro 31-3948), a potential disease-modifying antirheumatic drug
AU Bloxham, D. P.; Bradshaw, D.; Cashin, C. H.; Dodge, B. B.; Lewis, E. J.; Westmacott, D.; Self, C. R.
CS Biol. Dep., Roche Prod. Ltd., Welwyn Garden City, UK
SO Journal of Pharmacology and Experimental Therapeutics (1990), 252(3), 1331-40
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English
AB The biol. effects of a new potential disease-modifying anti-rheumatic drug, romazarit (Ro 31-3948, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid), were studied. In a 5-day adjuvant arthritis model, romazarit inhibited the development of hindpaw inflammation with a min. ED of 30 mg kg-1. Plasma levels of the acute phase reactants seromucoid and haptoglobin were also reduced. Romazarit was equally effective in adrenalectomized animals, indicating that the compound is not acting via stimulation of the pituitary/adrenal axis. When the developing adjuvant arthritis was extended to 15 days romazarit showed dose-related improvements of all the symptoms of arthritis with a min. ED of 25 mg kg-1. Romazarit caused a dose-dependent (range 20-250 mg kg-1) reduction in both the inflammatory and bony changes occurring during collagen arthritis in the rat, without any effect on anticollagen antibody titers except at the highest dose. Collagenase and prostaglandin E2 production in cultures of talus bones taken from rats with collagen arthritis were reduced by romazarit. In vitro romazarit was an extremely weak inhibitor of prostaglandin synthetase activity in both sheep seminal vesicle (IC50 6500 μM) and rat renal medulla (IC50 >300 μM) cell-free prepns. Romazarit showed little or no activity in models of acute inflammation such as rabbit skin edema, carrageenan pleurisy or UV-induced erythema. In both acute and chronic tests romazarit displayed no ulcerogenic potential. In comparison with the structurally similar compound clobuzarit, hepatic changes such as increases in catalase and peroxisome proliferation-associated 80,000 mol. weight protein were markedly less with romazarit. Clin. studies with romazarit are currently in progress.
IT **109543-76-2**, Romazarit
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antiarthritic mechanism and toxicity of)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:69594 CAPLUS
DN 112:69594
TI The effect of retinoids on the skin reaction and swelling seen 7 days after adjuvant injection in the rat paw
AU Cashin, C. H.; Lewis, E. J.
CS Dep. Anti-Inflammatory Biol., Roche Products Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SO Agents and Actions (1990), 29(1-2), 59-61
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English
AB The anti-inflammatory activity of a range of retinoids was tested on the skin reaction and swelling in the rat paw 7 days after adjuvant injection. Retinoids were generally effective at inhibiting both paw edema, in which their effect was delayed in onset, and the skin reaction. They were more active against the skin response. Arotinoids lacked anti-inflammatory activity but reduced the skin reaction. Drugs such as indomethacin were selectively anti-inflammatory. Dexamethasone and cyclosporin A were effective in reducing both parameters as was romazarit.
IT **109543-76-2**, Romazarit
RL: BIOL (Biological study)
(paw swelling and skin reaction after adjuvant-induced inflammation response to)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:105873 CAPLUS
DN 108:105873
TI Interactions between oxaprozin glucuronide and human serum albumin
AU Wells, D. S.; Janssen, F. W.; Ruelius, H. W.
CS Wyeth Lab., Philadelphia, PA, 19101-8299, USA
SO Xenobiotica (1987), 17(12), 1437-49
CODEN: XENOBH; ISSN: 0049-8254
DT Journal
LA English
GI



I

AB The 1st step in the interaction between oxaprozin glucuronide (I) and human serum albumin (HSA) is formation of a reversible complex which then leads to the following reactions; (a) acyl migration of the aglycon from position 1 to positions 2, 3 and 4 of the glucuronic acid moiety; (b) hydrolysis of the glycosidic bond; and (c) covalent binding of oxaprozin to the HSA mol. The isomers of oxaprozin glucuronide formed in (a) and the covalently bonded drug in (c) are also hydrolyzed to oxaprozin. Oxaprozin and ligands known to bind at Site II as classified by Sudlow et al. (1976), also called the benzodiazepine binding site (Mueller and Wollert 1975), inhibit these reactions with oxaprozin glucuronide, while ligands which are known to bind at other sites on HSA do not. Modification of a single tyrosine residue, located within Site II, with tetranitromethane, diisopropylfluorophosphate, and p-nitrophenylacetate causes significant reduction of the covalent binding of oxaprozin to HSA. Tetranitromethane modification of HSA decreases all 3 reactions, while not inhibiting the formation of the reversible complex, indicating that the tyrosine located in Site II (tyr-411) acts as the nucleophile in these reactions. Chemical modification of lysine residues has only a small effect on the reactions while modification of the lone free sulfhydryl (cys) in HSA has no effect.

IT 113202-73-6
RL: FORM (Formation, nonpreparative)
(formation of, from oxaprozin glucuronide, interaction with albumins of blood serum of humans in relation to)
RN 113202-73-6 CAPLUS
CN D-Gluconic acid, 2-(4,5-diphenyl-2-oxazolepropanoate) (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:496707 CAPLUS
DN 107:96707
TI Oxazolyl- and isoxazolylalkoxyalkylcarboxylates as antiarthritis agents
IN Machin, Peter James; Osbond, John Mervyn; Self, Christopher Raymond; Smithen, Carey Ernest; Tong, Brian Peter
PA Hoffmann-La Roche, F., und Co. A.-G., Switz.
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 220573	A1	19870506	EP 1986-114046	19861010
	EP 220573	B1	19911211		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8604708	A	19870418	DK 1986-4708	19861002
	FI 8604052	A	19870418	FI 1986-4052	19861007
	CA 1287058	A1	19910730	CA 1986-519957	19861007
	ZA 8607711	A	19880224	ZA 1986-7711	19861009
	US 4774253	A	19880927	US 1986-917566	19861010
	IL 80290	A1	19901129	IL 1986-80290	19861010
	AT 70270	E	19911215	AT 1986-114046	19861010
	AU 8663838	A1	19870430	AU 1986-63838	19861013
	AU 594382	B2	19900308		
	CS 255881	B2	19880315	CS 1986-7415	19861014
	HU 44245	A2	19880229	HU 1986-4282	19861015
	HU 195792	B	19880728		
	NO 8604128	A	19870421	NO 1986-4128	19861016
	NO 167284	B	19910715		
	NO 167284	C	19911023		
	JP 62093282	A2	19870428	JP 1986-244290	19861016
	ES 2002420	A6	19880801	ES 1986-2629	19861016
	SU 1514245	A3	19891007	SU 1986-4028303	19861016
	ES 2010537	A6	19891116	ES 1988-1315	19880429
PRAI	GB 1985-25578	A	19851017		
	GB 1986-17503	A	19860717		
	EP 1986-114046	A	19861010		

GI



II

AB The title compds. R4XOCR1R2COR3 [I; R1, R2 = alkyl; R3 = OH, alkoxy, amino; R4 = (alkylated) oxazolyl, isoxazolyl; X = alkylene] were prepared as antiarthritics. Me2C(OH)CO2Me was condensed with 2-(4-chlorophenyl)-4-chloromethyloxazole in DMF containing NaH. The resulting ester was saponified with NaOH in EtOH to give (chlorophenyl)oxazolylmethoxypropionic acid II. At 50 mg/kg/day orally, II reduced the average volume of inflamed rat paws by

L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
0.29 mL after 10 days. Capsules were prepd. contg I (unspecified) 100, lactose 150, cornstarch 20, and talc 5 mg.

IT 109544-36-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of)
RN 109544-36-7 CAPLUS
CN Propanoyl chloride, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT 109544-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
RN 109544-29-8 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-oxazolyl]methoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT 109543-76-2P 109543-77-3P 109543-78-4P
109543-79-5P 109543-80-8P 109543-81-9P
109543-82-0P 109543-83-1P 109543-84-2P
109543-85-3P 109543-86-4P 109543-95-5P
109543-96-6P 109543-97-7P 109543-98-8P
109543-99-9P 109544-00-5P 109544-01-6P
109544-02-7P 109544-03-8P 109544-09-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiarthritic)
RN 109543-76-2 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 109543-77-3 CAPLUS
CN Propanoic acid,
2-[[2-(3,4-dichlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-78-4 CAPLUS
CN Propanoic acid, 2-[[2-(3-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-79-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-methyl-2-[4-(methylthio)phenyl]-5-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 109543-80-8 CAPLUS
CN Propanamide,
2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-81-9 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 109543-82-0 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-ethyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-83-1 CAPLUS
CN Butanoic acid,
2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-ethyl- (9CI) (CA INDEX NAME)



RN 109543-84-2 CAPLUS
CN Propanoic acid, 2-[2-[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]ethoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 109543-85-3 CAPLUS
CN Butanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-86-4 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 109543-95-5 CAPLUS
CN Propanoic acid, 2-[[2-(4-fluorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109543-96-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 109543-97-7 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-5-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



RN 109543-98-8 CAPLUS
CN Propanoic acid, 2-[[5-(4-chlorophenyl)-2-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



RN 109543-99-9 CAPLUS
CN Propanoic acid, 2-[[4-(4-chlorophenyl)-2-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 109544-00-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 109544-01-6 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109544-02-7 CAPLUS
CN Propanoic acid, 2-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 109544-03-8 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-oxazolyl]methoxy]-2-methyl- (9CI)
(CA INDEX NAME)



L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 109544-09-4 CAPLUS
CN Propanoic acid, 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:148860 CAPLUS
DN 104:148860
TI Novel oxazole derivatives
IN Nakagawa, Akira; Inoe, Toshitaka; Saida, Masaru; Nakamura, Kunihiro; Tagami, Yoshihiro; Yatani, Terumi
PA Hisamitsu Pharmaceutical Co., Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60208971	A2	19851021	JP 1984-64409	19840330
PRAI JP 1984-64409		19840330		

GI



I



II

AB Oxazole derivs. I (R, R1 = H, halo; R2, R3 = H, lower alkyl; R4 = OH, substituted amino; n = 1, 2), useful as allergy inhibitors and immunity regulators, were prepared Thus, refluxing 1.49 g (chloromethyl)oxazole II
with 1.06 g HSCHMeCO2H in EtOH containing K2CO3 gave 2.24 g I (R-R2 = H; R3 = Me; R4 = OH; n = 1). Administration of 50 mg/kg p.o. I (R-R3 = H; R4 = OH; n = 2) to female mice sensitized with sheep erythrocytes showed 69.5% increase in plantar thickness, compared to 55.0% for Na N-(2-carboxyphenyl)-4-chloroanthranilate.
IT **75595-27-6P 100783-83-3P 100783-84-4P**
100783-87-7P 100783-89-9P 100783-91-3P
100783-94-6P 100783-97-9P 100783-98-0P
100783-99-1P 100784-01-8P 100784-09-6P
101397-90-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as allergy inhibitor and immunity regulator)
RN 75595-27-6 CAPLUS
CN Acetic acid, [[(2-phenyl-4-oxazolyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 100783-83-3 CAPLUS
CN Propanamide, 2-[[(2-phenyl-4-oxazolyl)methyl]thio]-N-2-thiazolyl- (9CI)

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



RN 100783-84-4 CAPLUS
CN Propanoic acid, 2-[[[2-(4-chlorophenyl)-4-oxazolyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 100783-87-7 CAPLUS
CN Propanoic acid, 2-[[[2-(4-fluorophenyl)-4-oxazolyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 100783-89-9 CAPLUS
CN Propanoic acid, 2-[[(5-methyl-2-phenyl-4-oxazolyl)methyl]thio]- (9CI) (CA
INDEX NAME)



RN 100783-91-3 CAPLUS
CN Propanoic acid, 2-[[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methyl]thio]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 100783-94-6 CAPLUS
CN Propanamide,
2-[[[2-(4-chlorophenyl)-4-oxazolyl]methyl]thio]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 100783-97-9 CAPLUS
CN Propanamide,
2-[[(5-methyl-2-phenyl-4-oxazolyl)methyl]thio]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 100783-98-0 CAPLUS
CN Morpholine,
4-[2-[[(5-methyl-2-phenyl-4-oxazolyl)methyl]thio]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 101397-90-4 CAPLUS
CN Propanamide, N-(4,5-dihydro-2-thiazolyl)-2-[[(2-phenyl-4-oxazolyl)methyl]thio]- (9CI) (CA INDEX NAME)



IT **100783-82-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, and amidation of, with aminothiazole)
RN 100783-82-2 CAPLUS
CN Propanoic acid, 2-[[(2-phenyl-4-oxazolyl)methyl]thio]- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 100783-99-1 CAPLUS
CN Piperidine,
1-[2-[[(5-methyl-2-phenyl-4-oxazolyl)methyl]thio]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 100784-01-8 CAPLUS
CN Propanamide, 2-[[(2-phenyl-4-oxazolyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 100784-09-6 CAPLUS
CN Propanamide,
2-[[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methyl]thio]-N-(3-methyl-2(3H)-thiazolylidene)- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:620734 CAPLUS
DN 93:220734
TI Semisynthetic penicillin
IN Cojocariu, Ioan; Cojocaru, Zenaida; Zvoristeanu, Virginia; Stavri, Natalia
PA Intreprinderea de Antibiotice, Rom.
SO Rom., 2 pp.
CODEN: RUXXA3
DT Patent
LA Romanian
PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI RO 64909	B	19790515	RO 1976-86605	19760628
PRAI RO 1976-86605	A	19760628		

GI



II

AB Treating 6-aminopenicillanic acid (I) with (heterocyclylthio)acetic acids gave N-acylation products II (R = H, Cl, Z = O; R = H, Cl, OMe, Z = S; R1 = Na, K), useful as bactericides (no data). Thus, treating I with [(2-phenyl-4-thiazolylmethyl)thio]acetic acid, dicyclohexylcarbodiimide, and Na2CO3 at room temperature and then adjusting to pH 2-2.5 gave II (R = R1 = H, Z = S).
IT **75595-22-1P 75595-23-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 75595-22-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[[(2-phenyl-4-oxazolyl)methyl]thio]acetyl]amino]-, monosodium salt, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 75595-23-2 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[2-(4-chlorophenyl)-4-oxazolyl]methyl]thio]acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 75595-27-6 75595-28-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-acylation of aminopenicillanic acid by)
RN 75595-27-6 CAPLUS
CN Acetic acid, [[(2-phenyl-4-oxazolyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 75595-28-7 CAPLUS
CN Acetic acid, [[[2-(4-chlorophenyl)-4-oxazolyl]methyl]thio]- (9CI) (CA

L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



```
=> => d que l8 stat
L5            31 SEA FILE=CAPLUS ABB=ON  PLU=ON  "KUWABARA KENJI"/AU
L6             7 SEA FILE=CAPLUS ABB=ON  PLU=ON  "AOKI TOMIYOSHI"/AU
L7            35 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 OR L6
L8             2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 AND (OXAZOLE OR HETEROCYCLIC
                  )

=> d 1-2 bib abs
```

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:868433 CAPLUS
DN 136:20062
TI Preparation of **heterocyclic** compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.
IN **Kuwabara, Kenji; Aoki, Tomiyoshi**
PA Nippon Shinyaku Co., Ltd., Japan
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062
AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic **heterocyclic** group; Het is a divalent aromatic **heterocyclic** group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:453023 CAPLUS
DN 135:46207
TI Preparation of **heterocyclic** derivatives as anticancer agents
IN Suzuki, Toshiyuki; **Aoki, Tomiyoshi**
PA Nippon Shinyaku Co., Ltd., Japan
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044195	A1	20010621	WO 2000-JP8781	20001213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2393358	AA	20010621	CA 2000-2393358	20001213
	AU 2001018873	A5	20010625	AU 2001-18873	20001213
	EP 1238974	A1	20020911	EP 2000-981657	20001213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003022884	A1	20030130	US 2002-149622	20020612
	US 6787546	B2	20040907		
PRAI	JP 1999-354101	A	19991214		
	JP 2000-202393	A	20000704		
	WO 2000-JP8781	W	20001213		

OS MARPAT 135:46207
AB The title compds. ABDE [A is heteroaryl or an oxide thereof; B is ethenylene; D is optionally substituted phenylene; and E is a group of general formula N(COR)SO2G (G is optionally substituted phenyl; and R is heteroaryl, heteroarylmethyl), etc.] are prepared A course of 5 injections of (E)-4-(2-(2-(N-(4-methoxybenzenesulfonyl)-N-(4-(2-pyridyl)piperazino)acetylamino)phenyl)ethenyl)pyridine 1-oxide dihydrochloride at 50 mg/kg i.v. gave 80% inhibition of tumor in mice. Formulations are given.
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)